Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford BioMedica ( (GB:OXB) ) has provided an update.
Oxford Biomedica has notified shareholders that its 2026 Annual General Meeting will be held on 7 May 2026 at the company’s Oxford headquarters, with the AGM notice and the 2025 annual report and accounts now dispatched and made available on its website. The AGM documentation has also been filed with the UK regulator’s National Storage Mechanism, underscoring the group’s adherence to listing requirements and providing investors with formal visibility into its governance timetable and reporting.
As a specialist cell and gene therapy CDMO, Oxford Biomedica’s confirmation of its AGM arrangements comes alongside continued emphasis on its global viral vector manufacturing capabilities and technology platforms. The combination of formal governance updates and its established operational footprint in the UK, France and the US highlights the company’s ongoing role as a key partner for biopharma clients seeking advanced development and manufacturing support in the fast-growing cell and gene therapy sector.
The most recent analyst rating on (GB:OXB) stock is a Sell with a £543.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on OXB Stock
According to Spark, TipRanks’ AI Analyst, OXB is a Neutral.
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global, quality and innovation-led contract development and manufacturing organisation specialising in cell and gene therapy. The company focuses on viral vector development and manufacturing, including lentiviral, AAV and adenoviral vectors, serving leading pharmaceutical and biotechnology clients from early-stage development through commercialisation across facilities in the UK, France and the US.
With three decades of experience in viral vectors, OXB offers proprietary technologies such as its fourth-generation TetraVecta lentiviral system and advanced AAV production platforms. The FTSE 250 and FTSE4Good constituent underpins its services with robust quality systems, analytical capabilities and regulatory expertise to support the delivery of life-changing therapies worldwide.
YTD Price Performance: -9.08%
Average Trading Volume: 380,144
Technical Sentiment Signal: Buy
Current Market Cap: £678.1M
See more data about OXB stock on TipRanks’ Stock Analysis page.